Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)
Study sponsor: Scynexis, Inc. · SCYX
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2021-09-01Actual
Enrollment · participants440Actual
Source updated2023-06-18Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.